Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit

IQWiG

15 September 2021 - Third new area of ​​application/those affected still live a good year on average - and thus longer than under the appropriate comparator therapy.

In an early benefit assessment, the IQWiG examined whether venetoclax in combination with a hypomethylating agent would give people with newly diagnosed acute myeloid leukaemia for whom intensive chemotherapy is not suitable.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder